

GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCH

Fellowship Program

University of Washington 2016 - 2018




W UNIVERSITY of WASHINGTON

ABOUT OUR COMPANY

Allergan, headquartered in Dublin, Ireland, is a unique, global pharmaceutical company among the leaders in Growth Pharma. Our company is focused on developing, manufacturing and commercializing innovative pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world. Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories. Our company also operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. We are an industry leader in research and development, with one of the broadest innovative development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally. With commercial operations in approximately 100 countries, our company is committed to working with physicians, pharmacists, healthcare providers and customers to provide patients with pharmaceuticals that help people around the world live longer, healthier lives.

OUR WORLD-CLASS R&D NETWORK



GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCH (GHEOR) MISSION

Allergan GHEOR Vision: To drive optimal access for Allergan products everywhere.



ABOUT OUR SCHOOL

The University of Washington is a world-class leader in health sciences education and has been consistently listed in US News and World Report as one of the top 10 institutions for its graduate programs. The University is particularly noted for its strong research programs and since 1974 has received more federal funds for research and training than any other public university in the United States. It fosters a highly collegial atmosphere between departments and academic units, creating a particularly attractive environment for such partnerships between the public and private sectors.

The Pharmaceutical Outcomes Research and Policy Program (PORPP) is housed within the University of Washington School of Pharmacy, which boasts nearly 120 years of academic and research success. Faculty in the program (1) provide advanced research training for graduate students, post-doctoral fellows and clinicians (PharmDs, MDs); (2) conduct rigorous scientific research in the pharmacoconomics and outcomes of pharmaceuticals and other health technologies, and (3) translate and disseminate the results of research into clinical practice and healthcare policy, with the goal of improving patient care.

PORPP faculty participating in the fellowship have been chosen both for their dedication to teaching and their excellence in research. Each is trained either as a health economist or health services researcher and all have an extensive history of effective pharmaco-economic and pharmaco-epidemiologic research.



ABOUT OUR FELLOWSHIP

The Allergan/University of Washington GHEOR Fellowship is a two-year program that provides training and hands-on experience in a broad-range of health economics and outcomes research topics. The program is structured to allow fellows to gain proficiency in health outcomes strategy and research as conducted in both academic and pharmaceutical industry settings.



THE FELLOWSHIP PROGRAM

Allergan and the University of Washington are pleased to offer two, 2-year GHEOR Fellowship positions for the academic year 2016-2018. Fellows will spend their first year at the University of Washington (Seattle, WA), and the second year at Allergan (Irvine, CA). The objective of the first year is to educate fellows on the principles and methods used in health economics and outcomes research. During the second year, fellows are provided with opportunities to gain practical knowledge and experience with the use of clinical, economic, and humanistic data by supporting the development and commercialization of pharmaceutical products. This will be accomplished by participating in work activities undertaken by the GHEOR team.

Compensation includes a competitive stipend, basic medical insurance, and holiday/vacation time. A Master's Degree is awarded upon completion of all course requirements and thesis project

FELLOWSHIP DIRECTORS



University of Washington

Beth Devine, PharmD, MBA, PhD, BCPS, FASHP
Associate Professor
Pharmaceutical Outcomes Research & Policy Program
1959 NE Pacific Avenue, H-375D
Box 357630
Seattle, WA 98195-7630
E-Mail: bdevine@uw.edu



Allergan, Inc.

Vaishali Patel, PharmD, MS
Senior Director, GHEOR
2525 Dupont Drive
Irvine, CA 92612
E-Mail: Patel_Vaishali@Allergan.com
Phone: (714) 246-6679



Fellowship Structure - First Year

Pictured from left to right: Sepideh Varon, PhD, Patrick Gillard, PharmD, MS, Jonathan W. Kowalski, PharmD, MS and Alon Yehoshua, PharmD, MS

FIRST YEAR OBJECTIVES

The objective of the first year is to provide the fellow with the research tools necessary for pharmacoeconomic and policy assessment. The fellow will be given an overview of pharmaceutical economics and general health policy, and taught methods of economic assessment, health services research, epidemiology, clinical research design, and biostatistical analyses.

The fellow will be assigned a Master's thesis project which is selected based on input from both Allergan as well as the University of Washington mentors. Fellows are highly encouraged to complete their MS project during their first year. Additionally, fellows will also engage in ongoing projects with Allergan throughout their first year, applying skills from previous pharmacy training as well as integrating new techniques developed from University of Washington courses. Applying learning to solve real-world problems is a constant focus of the fellowship.

The fellow's actual course of study will be developed on an individual basis with the Program Director, Dr. Beth Devine, but will consist of courses in biostatistics, epidemiology, pharmacoeconomics and outcomes research, and health and Pharmaceutical Policy.

AFTER COMPLETION OF THE FIRST-YEAR, THE FELLOW WILL HAVE A CLEAR UNDERSTANDING OF:

- General principles of economics and in particular how economics influences the use, cost, and availability of pharmaceuticals.
- The complex structure of drug policy and how it determines relationships between consumers, health care providers, insurers, payers, and government agencies.
- The breadth and scope of analytical methods needed for the assessment of Patient Reported Outcomes (PROs), economic modeling, retrospective database studies, and observational studies.
- Formulary development, maintenance and evaluation in institutional, managed care, and state-level government programs.



Fellowship Structure - Second Year

Pictured from left to right: Vanessa Shih, PharmD, MS and Katelyn Keyloun, PharmD, MS

SECOND YEAR OBJECTIVES

The second year of training will be at Allergan in Irvine, CA with the GHEOR department. This part of the program is designed to allow the fellow to learn about the role of pharmacoeconomics and outcomes research in the drug development and commercialization process within the industry setting. The research may be on an existing or experimental product, for a disease state that is of interest to Allergan.

In addition to completing individual research project(s), fellows will participate in ongoing pharmacoeconomic evaluations, outcomes research, and other projects in collaboration with the GHEOR team. These experiences will provide the fellow with opportunities to interact with team members in other departments at Allergan to learn how economic analyses and outcomes research are used throughout the pharmaceutical industry. Fellows will see firsthand how outcomes research is utilized to demonstrate the place of Allergan products in treatment pathways and its value.



ALLERGAN FELLOWSHIP MENTORS



Jan E. Hansen, PhD
Vice President, GHEOR



Jonathan W. Kowalski,
PharmD, MS
Vice President, GHEOR



Sepideh Varon, PhD
Senior Director, GHEOR



Vaishali Patel,
PharmD, MS
Senior Director, GHEOR



Patrick Gillard,
PharmD, MS
Director, GHEOR



Joanna Campbell, PhD
Director, GHEOR



Zsolt Hepp,
PharmD, MS
Manager, GHEOR

UNIVERSITY OF WASHINGTON PROGRAM FACULTY

- Anirban Basu, PhD
Professor and Stergachis Family Endowed
Director of PORPP
- Denise Boudreau, PhD
Affiliate Associate Professor
- Beth Devine, PharmD, MBA, PhD,
BCPS, FASHP
Associate Professor
- Josh Carlson, MPH, PhD
Assistant Professor
- Louis P. Garrison, Jr., PhD
Professor
- Ryan Hansen, PhD, PharmD
Assistant Professor
- Thomas K. Hazlet, PharmD, Dr. PH
Associate Professor
- Scott D. Ramsey, MD, PhD
Professor
- Sean D. Sullivan, PhD
Stergachis Family Professor and Dean of School
of Pharmacy
- David L. Veenstra, PharmD, PhD
Professor, Director of Graduate Programs



CURRENT FELLOWS

FIRST YEAR FELLOWS



Sarah Baradaran, PharmD

Sarah received her PharmD degree from the University of Washington (UW) School of Pharmacy in 2015. She completed a four-year clinical internship at The Everett Clinic, where she participated in P&T decision-making and conducted literature reviews and medication utilization evaluations. Sarah's clerkships at the FDA Department of Pharmacovigilance in two therapeutic areas allowed her to explore different methods of tracking and identifying adverse events, post-authorization. Her clerkship with Evidera's Retrospective Observational Studies team provided additional experience with evidence generation methods in outcomes research and real-world data.

Current coursework in epidemiology, biostatistics, and economic modeling are providing Sarah with a strong methods foundation. She looks forward to applying her skills and knowledge to her thesis project, which explores the identification and costs of adverse outcomes associated with colistin in severe MDR gram-negative infections. Sarah looks forward to working with the PORPP faculty and Allergan team.



Amy Tung, PharmD

Amy received her PharmD degree from the UW in 2015. Her interest in health economics and outcomes research (HEOR) started from the desire to blend her background working in the technology industry as a market researcher with her interest in pharmaceutical outcomes and health policy. Her passion for HEOR continued to grow while taking various pharmacoeconomics and managed care electives in pharmacy school, serving as president of UW's Academy of Managed Care Pharmacy chapter, and her experience writing dossiers for pharmaceutical companies as a consultant.

She is looking forward to building a strong foundation for becoming an effective health economics and outcomes researcher through coursework in biostatistics, epidemiology, economic evaluations, and patient-reported outcomes. For her thesis project, she will be conducting a retrospective claims-based analysis to assess the burden of interstitial cystitis in the US using a nationally representative dataset. Amy is excited for the opportunity to work with students and faculty at UW and Allergan.



Katelyn Keyloun, PharmD, MS

Katelyn R. Keyloun is a Washington State pharmacist (Graduated from University of Washington, June 2014) with a background in parasitology research. During the first year of the fellowship, she became involved with a health informatics project on use of pharmacogenomics testing in the UW health system under mentorship from Professor Beth Devine at UW. Her submitted thesis project is titled "A Retrospective Claims Analysis of Medication Adherence and Persistence Among Patients Taking Antidepressants for the Treatment of Major Depressive Disorder (MDD)".

During the second year of the fellowship, Katelyn has been under the mentorship of Patrick Gillard, GHEOR Director with a therapeutic focus on infectious disease. She is currently developing a manuscript from her thesis project results for MDD and performing additional analyses to further understand adherence and persistence in this population. In tandem, she is beginning work in infectious disease through developing statistical analysis plans and a patient satisfaction survey for ongoing projects supporting the economic value of Dalvance®. Katelyn is excited to tackle new projects throughout the second fellowship year at Allergan.

ABSTRACTS FROM FELLOWSHIP:

1. Keyloun K, Devine B. Estimating the cost-effectiveness of vortioxetine versus desvenlafaxine as first line therapy for mild to moderate major depressive disorder in remitted patients. ISPOR 20th Annual International Meeting, Philadelphia, PA, May 2015 (Poster)
2. Baradaran S, Keyloun K, Chin L, Pham J, Canestaro WJ, Devine B. Clinical evidence supporting pharmacogenomic biomarkers testing provided in US Food and Drug Administration drug labels: An update. UW School of Pharmacy Corporate Advisory Board, Seattle, WA, September 2015 (Poster)
3. Devine B, Khelifi M, Keyloun K, Hendrix N, Mathias P, Bock C, Tarczy-Hornoch P. Characterizing the frequency of pharmacogenomic biomarker-guided prescribing for drugs with pharmacogenomic biomarker information in the FDA labelling: a pilot study using data from an electronic health record. AMIA 2015 Annual Symposium, San Francisco, CA, November 2015 (Poster)

MANUSCRIPTS FROM FELLOWSHIP:

Mathias P, Hendrix N, Keyloun K, Khelifi M, Tarczy-Hornoch P, Devine B. Leveraging a Clinical Data Repository to Characterize the Landscape of Pharmacogenomic Biomarker-Guided Medication Use. September 2015 (under review at JAMIA)



Vanessa Shih, PharmD, MS

Vanessa received her doctorate of pharmacy from the University of California, San Francisco School of Pharmacy in 2014. In the first year of her fellowship, she completed her thesis titled "Assessing the burden of worsening self-reported vision in older Americans using the Health and Retirement Study" under the guidance of Professor Beth Devine.

During the second year of the fellowship, she has been under the mentorship of Joanna Campbell and Hitesh Chandwani in the ophthalmology therapeutic area. She has been performing additional analyses on her thesis project to estimate the association between onset of vision impairment and caregiving requirements to support the development of a manuscript. She has also been working on characterizing utilization of treatments for dry eye and will be working with electronic medical record data to understand real-world utilization of treatments for diabetic macular edema. She is excited to apply pharmacoeconomic principles to research in the industry setting during the second year of the fellowship.

ABSTRACTS FROM FELLOWSHIP:

Shih V, Devine B. Estimating the cost-effectiveness of left atrial appendage closure compared to warfarin for stroke prevention in atrial fibrillation. ISPOR 20th Annual International Meeting. May 16-20, 2015. Philadelphia, PA.



PAST FELLOWS

FELLOW

PUBLICATIONS DURING FELLOWSHIP

Tracy Yep, PharmD, MS

Years: 2013-2015

*Pharmacy Quality, Utilization,
and Clinical Programs Coordinator
Group Health
Seattle, WA*

MANUSCRIPTS FROM FELLOWSHIP

1. Yep T, Patel VD, Slejko JF, Devine EB. Comparing Total and Disease Related Healthcare Cost for Glaucoma Patients by Disease Severity: A Retrospective Claims Database Analysis. (In Progress)

ABSTRACTS FROM FELLOWSHIP

1. Yep T, Devine EB. A Cost Utility Analysis of CYP2D6 Pharmacogenetic Guided Dosing VS Standard Dosing of Risperidone for Treatment of Schizophrenia. ISPOR 19th Annual International Meeting, Montreal, QC, Canada, June 2014 (Poster)
2. Yep T, Patel V, Slejko J, Devine B. Comparing Total and Disease Related Healthcare Cost of Glaucoma Patients by Disease Severity: A Retrospective Claims Database Analysis. Investigative Ophthalmology & Visual Science. June 2015, Vol.56, 2129.
3. Comparing Total and Disease Specific Healthcare Cost for Glaucoma Patients Before and After the Index Diagnosis: A Retrospective Claims Database Analysis. ISPOR 20th Annual International Meeting. Philadelphia, PA, May 2015 (Poster)
4. Holekamp N, Dugel P, Yep T, Kiss S, Curkendall S, Fong DS, Patel V. Utilization of Anti-VEGFs for Diabetic Macular Edema in US Clinical Practice – an Analysis of the Vestrum Health® Database. The Retina Society 48th Annual Scientific Meeting Paris, France, October 2015 (Podium Session)

Chris Wallick, PharmD, MS

Years: 2012 – 2014

*Manager, Health Economics
and Outcomes Research
Avanir Pharmaceuticals
Aliso Viejo, CA*

MANUSCRIPTS FROM FELLOWSHIP

1. Stewart Williams JA, Wallick CJ, Byles JE, Doran CM. Assessing patterns of use of cardio-protective polypill component medicines in Australian women. *Drugs Aging* (2013)30:193-203
2. Wallick CJ, Sullivan SD, Hansen RN, Campbell JH, Kowalski JW. The Burden of Diabetic Macular Edema on a Commercially Insured Working Age Population. (2013). (In Progress)
3. Wallick CJ, Sullivan SD, Hansen RN, Campbell JH, Kowalski JW. The Cost of Diabetic Macular Edema in a Commercially Insured Working Age Population (2013). (In Progress)

MEETING ABSTRACTS FROM FELLOWSHIP

1. Wallick CJ, Sullivan SD, Kowalski J. An Overview of Medication Adherence and Persistence and its Importance in the Treatment of Glaucoma. University of Washington School of Pharmacy Corporate Advisory Board Meeting, September 13, 2012.

Zsolt Hepp, PharmD, MS

Years: 2012 – 2014

*Manager, Global Health Economics
and Outcomes Research
Allergan, Inc.
Irvine, CA*

MANUSCRIPTS FROM FELLOWSHIP

1. Hepp Z, David DW, Gillard P, Varon SF, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. *Cephalalgia*. 2015 May;35(6):478-88.
2. Forrester S, Hepp Z, Roth J, Wirtz H, Devine EB. Cost-effectiveness of a computerized provider order entry system in improving medication safety in ambulatory care. *Value Health*. 2014 Jun;17(4):340-9

MEETING ABSTRACTS FROM FELLOWSHIP

1. Hepp Z, David DW, Gillard P, Varon SF, Chia J, Mathew N, Hansen RN, Devine EB. Persistence and Switching Characteristics Among a Chronic Migraine Patient Population: A Retrospective Claims Analysis. Diamond Clinic Headache Update Conference. June 17-20, 2014. Orlando FL. Also to be presented at the European Headache and Migraine Trust International Congress. September 18-21, 2014. Copenhagen Denmark.
2. Hepp Z, Forrester S, Roth J, Wirtz H, Devine EB. Cost effectiveness of a computerized prescriber order entry system in improving medication safety: a case study in ambulatory care. International Society of Pharmacoeconomics and Outcomes Research 18th Annual International Meeting, May 18-22, 2013, New Orleans, LA.

**Joanna Sanderson,
PharmD, MS**

Years: 2011 – 2013

Consultant,
Health Economics
and Outcomes Research
Seattle, WA

MANUSCRIPTS FROM FELLOWSHIP

1. JC Sanderson, EB Devine, RB Lipton, LM Bloudek, SF Varon, AM Blumenfeld, PJ Goadsby, DC Buse, SD Sullivan. Headache-related health resource utilization in chronic and episodic migraine across six countries. *J Neurol Neurosurg Psychiatry*. 2013 Dec;84(12):1309-17
2. Bloudek LM, Sanderson JC, Varon SF, et al. Direct and indirect cost of chronic and episodic migraine in the United States. *In Progress*.

MEETING ABSTRACTS FROM FELLOWSHIP

1. Sanderson JC, Devine EB, Bloudek LM, Varon SF, Sullivan SD. Patient Perceptions of Prophylaxis Therapy in Chronic and Episodic Migraine. *The American Academy of Neurology Annual Meeting*. April 2012.
2. Sanderson JC, Devine EB, Bloudek LM, Varon SF, Sullivan SD. Patient Perceptions of Prophylaxis Therapy in Chronic and Episodic Migraine. *The International Society of Pharmacoeconomics and Outcomes Research Annual International Meeting*. June 2012.

Vincent W. Lin, PharmD, MS

Years: 2010 – 2012

Manager, Global Health Economics,
Oncology
Amgen
Thousand Oaks, CA

MANUSCRIPTS FROM FELLOWSHIP:

1. Lin VW, Ringold S, Devine BE. Comparison of Ustekinumab with other Biologic Agents for Treatment of Moderate-to-Severe Psoriasis: A Bayesian Network Meta-Analysis. *Arch Dermatol*. 2012 Dec;148(12):1403-10
2. Lin VW, Wright A, Flum DR, Alfonso RA, Garrison LP, Sullivan SD. Patients' experience and outcomes after laparoscopic adjustable gastric banding in Washington State. *Surg Obes Relat Dis*. 2013 Sep-Oct;9(5):701-5
3. Lin VW, Wright A, Flum DR, Alfonso RA, Sullivan SD. Health-Related Quality of Life in Patients after Laparoscopic Adjustable Gastric Banding Surgery Using EQ-5D (under review).

MEETING ABSTRACTS FROM FELLOWSHIP:

1. Lin VW, Wright A, Flum DR, Alfonso RA, Sullivan SD. Health-Related Quality of Life in Patients after Laparoscopic Adjustable Gastric Banding Surgery Using EQ-5D. *The Obesity Society Annual Meeting*, October 2011.
2. Lin VW, Yeh WS, Kowalski JW. Economic Evaluation for Screenings and Treatments of Diabetic Retinopathy and Diabetic Macular Edema: A Systematic Review. 2011 *International Society of Pharmacoeconomic and Outcomes Research*, May 2011.

Patrick Gillard, PharmD, MS

Years: 2009 – 2010

Director,
Global Health Economics
and Outcomes Research
Allergan, Inc.
Irvine, CA

MANUSCRIPTS FROM FELLOWSHIP:

1. Gillard PJ, Devine B, Varon SF, Liu L, Sullivan SD. Mapping from Disease-Specific Measures to Health-State Utility Values in Individuals with Migraine. *Value in Health* 2012;15(3):485-94.
2. Doan QV, Brashear A, Gillard PJ, Varon SF, Turkel CC, Vandenburg AM, Elovic EP. Relationship Between Disability Due to Upper-Limb Post-Stroke Spasticity and Health-Related Quality of Life and Caregiver Burden. *PM&R* 2012;4(1):4-10.

SELECT MEETING ABSTRACTS FROM FELLOWSHIP:

1. Graham GD, DiBonaventura M, Gillard PJ, Goren A, Denno M, Varon S, Zorowitz R. Productivity Loss and Indirect Costs Associated with Caring for Patients with Poststroke Spasticity. *American Academy of Physician Medicine and Rehabilitation*, November 2011.
2. Doan QV, Gillard P, Lu J, Halperin M, Hayward E, Varon S. Cost Effectiveness of BOTOX® for Treatment of Wrist and Hand Disability due to Post-stroke Spasticity in Scotland. 15th Congress of the European Federation of Neurological Societies, September 2011.

**Katharine S. Gries, PharmD,
MS, PhD**

Years: 2008 – 2010

Senior Research Associate,
Outcomes Research
Evidera
Seattle, WA

MANUSCRIPTS FROM FELLOWSHIP

1. Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment Success for Overactive Bladder with Urinary Urge Incontinence Refractory to Oral Antimuscarinics: A Review of Published Evidence. *BMC Urology*, 2009; 9(18)

SELECT MEETING ABSTRACTS FROM FELLOWSHIP:

1. Faber D, Gupta S, Boyer D, Patel S, Gries KS, Kowalski JW, Liu C, Lou J, Li XY, Whitcup, SM. Visual Function Improvement with OZURDEX® Treatment in Vitrectomized Subjects with Diabetic Macular Edema. *American Society Retina Specialist*. Vancouver, Canada, August 2010.
2. Gries KS, Patrick DL, Kowalski JW, Sullivan SD. Validity and Reliability of the Visual Function Questionnaire Utility Index in Individuals with Age-Related Macular Degeneration. *International Society for Pharmacoeconomics and Outcomes Research*, Atlanta, GA, May 2010.
3. Gries KS, Patel VD, Sullivan SD, Walt JG. Symptom Burden and Activity Limitation in Dry Eye Patients Seeking Ophthalmologists' Care. *American Academy of Ophthalmology Annual Meeting*, San Francisco, CA, Oct 2009.

**Jonathan H. Watanabe,
PharmD, MS, PhD**

Years: 2007 – 2009

Assistant Professor
UCSD Skaggs School of Pharmacy
San Diego, CA

MANUSCRIPTS FROM FELLOWSHIP:

1. Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment Success for Overactive Bladder with Urinary Urge Incontinence Refractory Oral Antimuscarinics. *BMC Urology*, 2009 Nov;20:9(18).
2. Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. Cost Analysis of Interventions for Antimuscarinic Refractory Patients with Overactive Bladder. *Urology*, 2010 Oct;76(4):835-40.
3. Sand P, Rovner E, Dmochowski R, Watanabe JH, Oefelein MG. Once-daily Trosipium Chloride 60 mg Extended Release is Safe and Effective in Subjects with the Overactive Bladder Syndrome who Use Multiple Concomitant Medications. *Drugs Aging*, 2011 Feb;1;28(2):151-60
4. Patel VD, Watanabe JH, Strauss JA, Dubey AT. Work productivity loss in patients with dry eye disease: an online survey. *Curr Med Res Opin*, 2011 May, 27(5):1041-8.

SELECT MEETING ABSTRACTS FROM FELLOWSHIP:

1. Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. Cost Analysis of Interventions for Antimuscarinic Refractory Patients with Overactive Bladder. *Podium Session. American Urological Association Annual Meeting*, April 2008.
2. Rovner E, Dmochowski, R, Watanabe J. Once-daily Trosipium Chloride 60 mg Extended Release is Safe and Effective in Patients with the Overactive Bladder Syndrome who Use Multiple Concomitant Medications. *Poster Session. Society for Urodynamics and Female Urology Winter Meeting*, February 2009.
3. Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. Three-year Cost Analysis of Sacral Neuromodulation, Intra-detrusor Injection of Botulinum Toxin Type A and Augmentation Cystoplasty for Overactive Bladder. *Moderated Poster Session. American Urological Association Annual Meeting*, May 2009.

APPLICATION ELIGIBILITY

Applicants for this fellowship must have a degree in pharmacy or health-related discipline and have some research experience (preference will be given to those with a high academic standing). Excellent written and verbal communication skills are also essential. Applicants will be required to submit their curriculum vitae, a letter describing their career goals, and three letters of recommendation. Selection of fellows will be made by a steering committee composed of the University of Washington faculty members and representatives from Allergan.

DEADLINE

The application deadline is
December 15, 2015
and the start date of the
Fellowship is **July 1, 2016**

APPLICATION INFORMATION

Interested students must apply to both the University of Washington Graduate School, as well as the Pharmaceutical Outcomes Research & Policy Program. The online application process can be found at:
<http://sop.washington.edu/departments-of-pharmacy/pharmaceutical-outcomes-research-policy-program-porpp/fellowship-opportunities/>

CONTACT INFORMATION

If you have any questions, please contact:

University of Washington

Penny Evans

Graduate Program Coordinator Department of Pharmacy

Box 357630

University of Washington

Seattle, WA 98195-7630

E-Mail: penny@u.washington.edu

Phone: (206) 616-1383

Fax: (206) 543-3835

Allergan, Inc.

Patrick Gillard, PharmD, MS

Director, GHEOR

2525 Dupont Drive

Irvine, CA 92612

E-Mail: Gillard_Patrick@allergan.com

Phone: (714) 246-2354